Streetbeat News

Products Services

AORT

Artivion has announced the presentation of interim data from its AMDS PERSEVERE trial at the 37th European Association for Cardio-Thoracic Surgery Annual Meeting. The data shows a significant reduction in all-cause mortality with AMDS.

Portfolio Pulse from Benzinga Newsdesk

October 05, 2023 | 8:10 pm

ONCT

Oncternal Therapeutics has announced the first patient has been dosed in the Phase 1/2 study of ONCT-534, a dual-action androgen receptor inhibitor for patients with metastatic castration-resistant prostate cancer. The company plans to advance the dose escalation portion of the study quickly, with patient enrollment across the U.S. and in the U.K. in early 2024. Initial clinical data is expected in the first half of 2024.

Portfolio Pulse from Benzinga Newsdesk

October 05, 2023 | 8:01 pm

KO

PepsiCo, Inc. (NYSE:KO) shares are trading lower by 5.03% due to a decrease in shopping demand as a result of the use of appetite-suppressing medications and overall market weakness. The rise in Treasury yields and the potential shift of investors from dividend-yielding stocks to fixed-income investments like bonds due to increasing interest rates could further exert downward pressure on Pepsi's stock price.

Portfolio Pulse from Henry Khederian

October 05, 2023 | 7:58 pm

AAPL

A popular YouTuber, JerryRigEverything, has conducted an experiment to determine the amount of Grade 5 Titanium in Apple's new iPhone 15 Pro and Pro Max models. The estimated value of the titanium in each iPhone model is between $9 and $40, with the actual figure likely closer to the lower end due to Apple's purchasing power. Apple has promoted the use of this 'aerospace-grade' material for its durability and lightweight properties.

Portfolio Pulse from AJ Fabino

October 05, 2023 | 7:49 pm

ATVI

'Diablo 4' is set to launch on Valve's Steam platform on October 17, four months after its exclusive release on Activision Blizzard's Battle.net platform. This is the second Blizzard game to be released on Steam, following 'Overwatch 2'. The move is aimed at breaking down barriers between gaming communities. The Steam launch coincides with the start of Diablo 4's Season 2, as the game seeks to regain momentum after a decline in interest due to update issues and a lack of endgame content.

Portfolio Pulse from Franca Quarneti

October 05, 2023 | 7:33 pm

APLS

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) reported strong demand for its product SYFOVRE, with preliminary U.S. revenue of approximately $74 million in Q3. The company distributed around 37,000 commercial vials and 10,000 samples to physician practices in Q3, and over 100,000 total vials have been delivered to date. Shares of APLS were up 6.73% at $40.15 at the time of publication.

Portfolio Pulse from Ryan Gustafson

October 05, 2023 | 7:24 pm

ADBE

AFRM

AMZN

Adobe Inc has released its annual holiday shopping forecast, predicting record-breaking deals this season. The company expects U.S. consumers to spend over $220 billion in online holiday shopping, a 5% YoY growth. Adobe also anticipates increased use of 'buy-now-pay-later' services like those offered by Affirm Holdings through its partnership with Amazon and other retailers. Despite falling prices for online goods, Adobe expects consumers to spend more on online holiday purchases this year.

Portfolio Pulse from Aaron Bry

October 05, 2023 | 7:04 pm

NVS

TCNNF

WBA

Dymapak, a global manufacturer of child-resistant packaging solutions, has introduced a new child-resistant Consumer Packaged Goods (CPG) packaging solution called 'Squeeze and Turn Tin'. The product is 100% curbside recyclable and offers an airtight seal and metal-on-metal construction. Companies such as Novartis AG, Walgreens Boots Alliance Inc, and Trulieve Cannabis Corp rely on Dymapak's solutions.

Portfolio Pulse from Joana Scopel

October 05, 2023 | 6:58 pm

AMGN

A U.S. FDA panel has voted against the reliability of late-stage data for Amgen's lung cancer drug. This could potentially impact the approval process of the drug.

Portfolio Pulse from Benzinga Newsdesk

October 05, 2023 | 6:39 pm

NBIX

Neurocrine Biosciences Inc (NBIX) released positive topline data from the Phase 3 CAHtalyst Pediatric Study of crinecerfont in children and adolescents with classic congenital adrenal hyperplasia (CAH). The study met its primary endpoint, demonstrating a significant decrease in serum androstenedione from baseline at Week 4 versus placebo. Approximately 30% of participants receiving crinecerfont achieved a reduction to a physiologic GC dose while maintaining androgen control compared to 0% of participants receiving a placebo. NBIX shares are up 3.74% at $114.83.

Portfolio Pulse from Vandana Singh

October 05, 2023 | 6:38 pm